gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Abuse Potential

Conditions

Abuse Potential

Trial Timeline

Apr 30, 2021 โ†’ Dec 31, 2021

About gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo

gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo is a approved stage product being developed by Viatris for Abuse Potential. The current trial status is completed. This product is registered under clinical trial identifier NCT05319756. Target conditions include Abuse Potential.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05319756ApprovedCompleted

Competing Products

15 competing products in Abuse Potential

See all competitors